271 related articles for article (PubMed ID: 12020728)
1. Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months.
King DL; Arendash GW
Physiol Behav; 2002 Apr; 75(5):627-42. PubMed ID: 12020728
[TBL] [Abstract][Full Text] [Related]
2. Intra- and intertask relationships in a behavioral test battery given to Tg2576 transgenic mice and controls.
Arendash GW; King DL
Physiol Behav; 2002 Apr; 75(5):643-52. PubMed ID: 12020729
[TBL] [Abstract][Full Text] [Related]
3. Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease.
King DL; Arendash GW; Crawford F; Sterk T; Menendez J; Mullan MJ
Behav Brain Res; 1999 Sep; 103(2):145-62. PubMed ID: 10513583
[TBL] [Abstract][Full Text] [Related]
4. Use of multimetric statistical analysis to characterize and discriminate between the performance of four Alzheimer's transgenic mouse lines differing in Abeta deposition.
Leighty RE; Nilsson LN; Potter H; Costa DA; Low MA; Bales KR; Paul SM; Arendash GW
Behav Brain Res; 2004 Aug; 153(1):107-21. PubMed ID: 15219712
[TBL] [Abstract][Full Text] [Related]
5. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes.
Arendash GW; King DL; Gordon MN; Morgan D; Hatcher JM; Hope CE; Diamond DM
Brain Res; 2001 Feb; 891(1-2):42-53. PubMed ID: 11164808
[TBL] [Abstract][Full Text] [Related]
6. Maintained synaptophysin immunoreactivity in Tg2576 transgenic mice during aging: correlations with cognitive impairment.
King DL; Arendash GW
Brain Res; 2002 Feb; 926(1-2):58-68. PubMed ID: 11814407
[TBL] [Abstract][Full Text] [Related]
7. Three weeks of running wheel exposure improves cognitive performance in the aged Tg2576 mouse.
Nichol KE; Parachikova AI; Cotman CW
Behav Brain Res; 2007 Dec; 184(2):124-32. PubMed ID: 17698211
[TBL] [Abstract][Full Text] [Related]
8. Early impairment in a water-finding test in a longitudinal study of the Tg2576 mouse model of Alzheimer's disease.
Kishimoto Y; Higashihara E; Fukuta A; Nagao A; Kirino Y
Brain Res; 2013 Jan; 1491():117-26. PubMed ID: 23142630
[TBL] [Abstract][Full Text] [Related]
9. Progressive age-related impairment of cognitive behavior in APP23 transgenic mice.
Kelly PH; Bondolfi L; Hunziker D; Schlecht HP; Carver K; Maguire E; Abramowski D; Wiederhold KH; Sturchler-Pierrat C; Jucker M; Bergmann R; Staufenbiel M; Sommer B
Neurobiol Aging; 2003; 24(2):365-78. PubMed ID: 12498971
[TBL] [Abstract][Full Text] [Related]
10. Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease.
Dong H; Csernansky CA; Martin MV; Bertchume A; Vallera D; Csernansky JG
Psychopharmacology (Berl); 2005 Aug; 181(1):145-52. PubMed ID: 15778881
[TBL] [Abstract][Full Text] [Related]
11. Progressive cognitive impairment and anxiety induction in the absence of plaque deposition in C57BL/6 inbred mice expressing transgenic amyloid precursor protein.
Lee KW; Lee SH; Kim H; Song JS; Yang SD; Paik SG; Han PL
J Neurosci Res; 2004 May; 76(4):572-80. PubMed ID: 15114629
[TBL] [Abstract][Full Text] [Related]
12. A TgCRND8 Mouse Model of Alzheimer's Disease Exhibits Sexual Dimorphisms in Behavioral Indices of Cognitive Reserve.
Granger MW; Franko B; Taylor MW; Messier C; George-Hyslop PS; Bennett SA
J Alzheimers Dis; 2016; 51(3):757-73. PubMed ID: 26890738
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Effects of Human Amniotic Epithelial Stem Cells in a Transgenic Mouse Model of Alzheimer's Disease.
Kim KY; Suh YH; Chang KA
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290355
[TBL] [Abstract][Full Text] [Related]
14. Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice.
Plaschke K; Kopitz J; Siegelin M; Schliebs R; Salkovic-Petrisic M; Riederer P; Hoyer S
J Alzheimers Dis; 2010; 19(2):691-704. PubMed ID: 20110613
[TBL] [Abstract][Full Text] [Related]
15. Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging.
Jensen MT; Mottin MD; Cracchiolo JR; Leighty RE; Arendash GW
Neuroscience; 2005; 130(3):667-84. PubMed ID: 15590151
[TBL] [Abstract][Full Text] [Related]
16. Early-onset subicular microvascular amyloid and neuroinflammation correlate with behavioral deficits in vasculotropic mutant amyloid beta-protein precursor transgenic mice.
Xu F; Grande AM; Robinson JK; Previti ML; Vasek M; Davis J; Van Nostrand WE
Neuroscience; 2007 Apr; 146(1):98-107. PubMed ID: 17331655
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of hAPPswe impairs rewarded alternation and contextual fear conditioning in a transgenic mouse model of Alzheimer's disease.
Corcoran KA; Lu Y; Turner RS; Maren S
Learn Mem; 2002; 9(5):243-52. PubMed ID: 12359834
[TBL] [Abstract][Full Text] [Related]
18. Comparative studies using the Morris water maze to assess spatial memory deficits in two transgenic mouse models of Alzheimer's disease.
Edwards SR; Hamlin AS; Marks N; Coulson EJ; Smith MT
Clin Exp Pharmacol Physiol; 2014 Oct; 41(10):798-806. PubMed ID: 25115283
[TBL] [Abstract][Full Text] [Related]
19. Aspects of spatial memory and behavioral disinhibition in Tg2576 transgenic mice as a model of Alzheimer's disease.
Ognibene E; Middei S; Daniele S; Adriani W; Ghirardi O; Caprioli A; Laviola G
Behav Brain Res; 2005 Jan; 156(2):225-32. PubMed ID: 15582108
[TBL] [Abstract][Full Text] [Related]
20. Age-dependent phenotypic characteristics of a triple transgenic mouse model of Alzheimer disease.
Pietropaolo S; Feldon J; Yee BK
Behav Neurosci; 2008 Aug; 122(4):733-47. PubMed ID: 18729626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
